Keyphrases
Graft-versus-host Disease (GvHD)
100%
Bone Marrow Transplantation
79%
Chronic Myeloid Leukemia
75%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
69%
Transplantation
47%
Allogeneic Bone Marrow Transplantation
43%
Marrow
41%
Leukemia
39%
Acute Myeloid Leukemia
35%
T Cells
32%
Canine
28%
Bone Marrow
27%
Donor Lymphocyte Infusion
25%
Hematopoietic Stem Cell Transplantation
24%
Marrow Transplantation
22%
Interferon-α (IFN-α)
22%
Acute Leukemia
22%
Dendritic Cells
20%
Stem Cell Transplantation
20%
Graft-versus-leukemia Effect
18%
Myelodysplastic Syndrome
18%
Chemotherapy
16%
Working Party
16%
Unrelated Donor
16%
Overall Survival
15%
Total Body Irradiation
15%
HLA-identical Sibling
14%
Adoptive Immunotherapy
13%
Hematopoietic Stem Cells
13%
Transfusion
13%
Chimerism
13%
Engraftment
12%
High Risk
12%
Transplant-related Mortality
12%
Hydroxyurea
12%
Cyclophosphamide
11%
Leukemia Patients
11%
Remission
11%
Acute Lymphoblastic Leukemia
11%
Chimera
11%
Stem Cells
11%
Allogeneic
11%
Reduced-intensity Conditioning
11%
Venous Disease
11%
Antileukemic Activity
10%
Chronic Phase
10%
Risk Factors
10%
Complete Remission
10%
Peripheral Blood
10%
Leukemia-derived Dendritic Cells
10%
Medicine and Dentistry
Bone Marrow Transplantation
68%
Chronic Myelogenous Leukemia
54%
Leukemia
48%
Graft Versus Host Reaction
45%
Transplantation
40%
Diseases
38%
Allogeneic Stem Cell Transplantation
34%
Acute Myeloid Leukemia
34%
T Cell
33%
Allogenic Bone Marrow Transplantation
27%
Acute Leukemia
22%
Myelodysplastic Syndrome
22%
Hematopoietic Cell
19%
Allogeneic Hematopoietic Stem Cell Transplantation
18%
Conditioning
18%
Stem Cell Therapy
18%
Dendritic Cell
17%
Hematopoietic Stem Cell Transplantation
17%
Lymphocyte
14%
Graft Versus Leukemia Effect
14%
Overall Survival
13%
Stem Cell
12%
Allograft
12%
Lymphocyte Transfusion
11%
Chronic Graft Versus Host Disease
11%
Acute Myelogenous Leukemia
11%
Acute Graft Versus Host Disease
10%
Adoptive Immunotherapy
10%
Acute Lymphoblastic Leukemia
10%
Whole Body Radiation
10%
Donor Lymphocyte Infusion
9%
Interferon
9%
Reduced Intensity Conditioning
8%
Vein Occlusion
8%
Immunotherapy
8%
In Vitro
7%
Cancer
7%
Infection
7%
Neoplasm
7%
Cyclosporine
7%
Imatinib
6%
Chimera
6%
Cytokine
6%
Hematologic Malignancy
6%
Immunosuppressive Treatment
6%
Aplastic Anemia
6%
Globulin
6%
Engraftment
6%
Tumor Necrosis Factor
6%
Bone Marrow Cell
6%
Immunology and Microbiology
Graft-Versus-Host Disease
55%
Myeloid
53%
Bone Marrow Transplantation
48%
T Cell
43%
Allogeneic Stem Cell Transplantation
30%
Conditioning
29%
Lymphocyte
26%
Hematopoietic Cell
25%
Dendritic Cell
19%
Acute Graft Versus Host Disease
18%
Allogeneic Hematopoietic Stem Cell Transplantation
18%
Hematopoietic Stem Cell Transplantation
18%
Stem Cell Transplantation
17%
Stem Cell
16%
Allogeneic Bone Marrow Transplantation
14%
Chimera
14%
Overall Survival
13%
Chronic Graft Versus Host Disease
13%
Engraftment
13%
B Cell
11%
Adoptive Immunotherapy
10%
Immunotherapy
10%
Anti-Thymocyte Globulin
9%
Cyclophosphamide
9%
Allograft
9%
Drug Megadose
8%
Platelet
8%
Globulin
7%
Cytokine
7%
CD34
7%
Ciclosporin
6%
Tumor Necrosis Factor
6%
Leukocyte
6%
Peptides
6%
Immunity
6%
Methotrexate
5%
Cell Transplantation
5%
Interferon Type I
5%
Minor Histocompatibility Antigen
5%
Natural Killer Cell
5%
Tumor Necrosis Factor Alpha
5%
Bone Marrow Cell
5%
Monoclonal Antibody
5%
Blood Level
5%